An update on the management of sporadic desmoid-type fibromatosis: A European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG)

Bernd Kasper; C. Baumgarten; the Desmoid Working Group; J. Garcia; S. Bonvalot; R. Haas; F. Haller; P. Hohenberger; N. Penel; C. Messiou; W. T. van der Graaf; Alessandro Gronchi; S. Bauer; L. H. Lindner; K. Verhoef

doi:10.1093/annonc/mdx323

An update on the management of sporadic desmoid-type fibromatosis: A European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG)

Bernd Kasper^*
, C. Baumgarten
, the Desmoid Working Group
, J. Garcia
, S. Bonvalot
, R. Haas
, F. Haller
, P. Hohenberger
, N. Penel
, C. Messiou
, W. T. van der Graaf
, Alessandro Gronchi^*
, S. Bauer
, L. H. Lindner
, K. Verhoef

^*Corresponding author for this work

Heidelberg University
SPAEN Sarcoma PAtients EuroNet e.V
Institut Curie (Paris)
Friedrich-Alexander University Erlangen-Nürnberg
Centre Oscar Lambret
Royal Marsden Hospital, London
IRCCS Fondazione Istituto Nazionale per lo studio e la cura dei tumori - Milano
Universite Claude Bernard Lyon 1
Netherlands Cancer Institute
University College London
Klinikum der Universität München
Hannover Medical School
Universitätsspital Basel
Charles University
University of Texas MD Anderson Cancer Center
Hospital Universitario Virgen del Rocio
Maria Sklodowska-Curie Institute of Oncology
Centre Georges-François Leclerc
Hospital Vall d'Hebron & ARADyAL research network
University Hospital Münster
Sarcoma Patients EuroNet (SPAEN)
Institute of Cancer Research
The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital
Leiden University Medical Centre

Research output: Contribution to journal › Review article › Popular

358 Citations (Scopus)

52 Downloads (Pure)

Abstract

Desmoid-type fibromatosis is a rare and locally aggressive monoclonal, fibroblastic proliferation characterized by a variable and often unpredictable clinical course. Currently, there is no established or evidence-based treatment approach available for this disease. Therefore, in 2015 the European Desmoid Working Group published a position paper giving recommendations on the treatment of this intriguing disease. Here, we present an update of this consensus approach based on professionals' AND patients' expertise following a round table meeting bringing together sarcoma experts from the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group with patients and patient advocates from Sarcoma PAtients EuroNet. In this paper, we focus on new findings regarding the prognostic value of mutational analysis in desmoid-type fibromatosis patients and new systemic treatment options.

Original language	English
Pages (from-to)	2399-2408
Number of pages	10
Journal	Annals of Oncology
Volume	28
Issue number	10
DOIs	https://doi.org/10.1093/annonc/mdx323
Publication status	Published - Oct 2017

Bibliographical note

Publisher Copyright:
© The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1093/annonc/mdx323Licence: CC BY-NC

An update on the management of sporadicFinal published version, 729 KBLicence: CC BY-NC

Fingerprint

Dive into the research topics of 'An update on the management of sporadic desmoid-type fibromatosis: A European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG)'. Together they form a unique fingerprint.

Cite this

Kasper, B., Baumgarten, C., the Desmoid Working Group, Garcia, J., Bonvalot, S., Haas, R., Haller, F., Hohenberger, P., Penel, N., Messiou, C., van der Graaf, W. T., Gronchi, A., Bauer, S., Lindner, L. H., & Verhoef, K. (2017). An update on the management of sporadic desmoid-type fibromatosis: A European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG). Annals of Oncology, 28(10), 2399-2408. https://doi.org/10.1093/annonc/mdx323

Kasper, Bernd ; Baumgarten, C. ; the Desmoid Working Group et al. / An update on the management of sporadic desmoid-type fibromatosis : A European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG). In: Annals of Oncology. 2017 ; Vol. 28, No. 10. pp. 2399-2408.

@article{d08c9579c5cb4f1eb359bdd1243ffb40,

title = "An update on the management of sporadic desmoid-type fibromatosis: A European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG)",

abstract = "Desmoid-type fibromatosis is a rare and locally aggressive monoclonal, fibroblastic proliferation characterized by a variable and often unpredictable clinical course. Currently, there is no established or evidence-based treatment approach available for this disease. Therefore, in 2015 the European Desmoid Working Group published a position paper giving recommendations on the treatment of this intriguing disease. Here, we present an update of this consensus approach based on professionals' AND patients' expertise following a round table meeting bringing together sarcoma experts from the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group with patients and patient advocates from Sarcoma PAtients EuroNet. In this paper, we focus on new findings regarding the prognostic value of mutational analysis in desmoid-type fibromatosis patients and new systemic treatment options.",

author = "Bernd Kasper and C. Baumgarten and \{the Desmoid Working Group\} and J. Garcia and S. Bonvalot and R. Haas and F. Haller and P. Hohenberger and N. Penel and C. Messiou and \{van der Graaf\}, \{W. T.\} and Alessandro Gronchi and S. Bauer and Blay, \{J. Y.\} and \{van Coevorden\}, F. and P. Dileo and D{\"u}rr, \{H. R.\} and M. Fiore and V. Gr{\"u}nwald and R. Jones and I. Judson and C. Kettelhack and K. Kopeckova and A. Lazar and Lindner, \{L. H.\} and J. Martin-Broto and P. Rutkowski and S. Stacchiotti and E. Stoeckle and C. Valverde and K. Verhoef and E. Wardelmann and M. Wartenberg",

year = "2017",

month = oct,

doi = "10.1093/annonc/mdx323",

language = "English",

volume = "28",

pages = "2399--2408",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd.",

number = "10",

}

Kasper, B, Baumgarten, C, the Desmoid Working Group, Garcia, J, Bonvalot, S, Haas, R, Haller, F, Hohenberger, P, Penel, N, Messiou, C, van der Graaf, WT, Gronchi, A, Bauer, S, Lindner, LH & Verhoef, K 2017, 'An update on the management of sporadic desmoid-type fibromatosis: A European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG)', Annals of Oncology, vol. 28, no. 10, pp. 2399-2408. https://doi.org/10.1093/annonc/mdx323

An update on the management of sporadic desmoid-type fibromatosis: A European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG). / Kasper, Bernd; Baumgarten, C.; the Desmoid Working Group et al.
In: Annals of Oncology, Vol. 28, No. 10, 10.2017, p. 2399-2408.

Research output: Contribution to journal › Review article › Popular

TY - JOUR

T1 - An update on the management of sporadic desmoid-type fibromatosis

T2 - A European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG)

AU - Kasper, Bernd

AU - Baumgarten, C.

AU - the Desmoid Working Group

AU - Garcia, J.

AU - Bonvalot, S.

AU - Haas, R.

AU - Haller, F.

AU - Hohenberger, P.

AU - Penel, N.

AU - Messiou, C.

AU - van der Graaf, W. T.

AU - Gronchi, Alessandro

AU - Bauer, S.

AU - Blay, J. Y.

AU - van Coevorden, F.

AU - Dileo, P.

AU - Dürr, H. R.

AU - Fiore, M.

AU - Grünwald, V.

AU - Jones, R.

AU - Judson, I.

AU - Kettelhack, C.

AU - Kopeckova, K.

AU - Lazar, A.

AU - Lindner, L. H.

AU - Martin-Broto, J.

AU - Rutkowski, P.

AU - Stacchiotti, S.

AU - Stoeckle, E.

AU - Valverde, C.

AU - Verhoef, K.

AU - Wardelmann, E.

AU - Wartenberg, M.

PY - 2017/10

Y1 - 2017/10

N2 - Desmoid-type fibromatosis is a rare and locally aggressive monoclonal, fibroblastic proliferation characterized by a variable and often unpredictable clinical course. Currently, there is no established or evidence-based treatment approach available for this disease. Therefore, in 2015 the European Desmoid Working Group published a position paper giving recommendations on the treatment of this intriguing disease. Here, we present an update of this consensus approach based on professionals' AND patients' expertise following a round table meeting bringing together sarcoma experts from the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group with patients and patient advocates from Sarcoma PAtients EuroNet. In this paper, we focus on new findings regarding the prognostic value of mutational analysis in desmoid-type fibromatosis patients and new systemic treatment options.

AB - Desmoid-type fibromatosis is a rare and locally aggressive monoclonal, fibroblastic proliferation characterized by a variable and often unpredictable clinical course. Currently, there is no established or evidence-based treatment approach available for this disease. Therefore, in 2015 the European Desmoid Working Group published a position paper giving recommendations on the treatment of this intriguing disease. Here, we present an update of this consensus approach based on professionals' AND patients' expertise following a round table meeting bringing together sarcoma experts from the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group with patients and patient advocates from Sarcoma PAtients EuroNet. In this paper, we focus on new findings regarding the prognostic value of mutational analysis in desmoid-type fibromatosis patients and new systemic treatment options.

UR - https://www.scopus.com/pages/publications/85030528270

U2 - 10.1093/annonc/mdx323

DO - 10.1093/annonc/mdx323

M3 - Review article

C2 - 28961825

AN - SCOPUS:85030528270

SN - 0923-7534

VL - 28

SP - 2399

EP - 2408

JO - Annals of Oncology

JF - Annals of Oncology

IS - 10

ER -

Kasper B, Baumgarten C, the Desmoid Working Group, Garcia J, Bonvalot S, Haas R et al. An update on the management of sporadic desmoid-type fibromatosis: A European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG). Annals of Oncology. 2017 Oct;28(10):2399-2408. doi: 10.1093/annonc/mdx323

An update on the management of sporadic desmoid-type fibromatosis: A European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG)

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this